Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | DKK1 | O94907 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19458854 | 1.00 | BPTF (0.55) | BPTFPTPN11HTR7SYKHRH4 | |
| SCHEMBL2272239 | 0.77 | HTR3E (0.47) | HTR7HRH4DKK1 | |
| Hydrochloric Acid SCHEMBL2272152 | 0.76 | HTR3E (0.46) | HTR7HRH4DKK1 | |
| Hydrochloric Acid SCHEMBL16684961 | 0.76 | HTR3E (0.46) | HTR7HRH4DKK1 | |
| SCHEMBL23174122 | 0.75 | DKK1 (0.45) | BPTFPTPN11SYKHRH4PIM1 | |
| SCHEMBL1588643 | 0.74 | HRH4 (0.66) | HRH4 | |
| SCHEMBL26684538 | 0.74 | HRH4 (0.45) | HTR7HRH4 | |
| SCHEMBL1588660 | 0.74 | HRH4 (0.66) | HRH4 | |
| SCHEMBL23152497 | 0.74 | HTR7 (0.46) | HTR7HRH4LOXLOXL3LOXL2 | |
| SCHEMBL22886404 | 0.74 | LDHA (0.49) | BPTFHRH4PIM1DKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-04 | — | — | US | disclosed |
| US-8841287-B2 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-23 | — | — | US | disclosed |
| EP-2315521-B1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH1 | BPTF 663/4885PTPN11 1281/4885HTR7 150/4885 |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | BPTF 667/4885PTPN11 1369/4885HTR7 147/4885 |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH2 | BPTF 667/4885PTPN11 1369/4885HTR7 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.